Sunshine Biopharma (SBFM) Change in Accured Expenses (2012 - 2026)

Sunshine Biopharma's Change in Accured Expenses history runs 15 years deep, the most recent figure standing at -$455836.0 for Q1 2026.

• Quarterly Change in Accured Expenses rose 6.21% year-over-year to -$455836.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$159783.0 (down 107.25% YoY) and the FY2025 annual result came in at -$189956.0, down 104.77% from the prior year.
• Change in Accured Expenses was -$455836.0 for Q1 2026 at Sunshine Biopharma, up from -$565040.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $1.8 million in Q4 2024 and bottomed at -$1.0 million in Q2 2023.
• A 5-year average of $113266.8 and a median of -$73661.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 2084.3% — and 2023, when it plunged 10997.79%.
• Sunshine Biopharma's Change in Accured Expenses stood at -$485554.0 in 2022, then slumped by 59.85% to -$776161.0 in 2023, then jumped by 326.07% to $1.8 million in 2024, then plunged by 132.2% to -$565040.0 in 2025, then rose by 19.33% to -$455836.0 in 2026.
• Business Quant data shows SBFM's Change in Accured Expenses at -$455836.0 in Q1 2026, -$565040.0 in Q4 2025, and $1.2 million in Q3 2025.